Randomized Phase 2 Study of Guadecitabine in Patients with HMA-Naive Higher Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Savona, M.R, Garcia-Manero, G, Roboz, G.J, Walsh, K.J, Kropf, P.L, Issa, J.P, O’Connell, C.L, Tibes, R, Yee, K.W.L, Stock, W, Lunin, S, Berdeja, J.G, Naim, S, Hao, Y, Azab, M, Kantarjian, H
Published in Leukemia research (01.04.2017)
Published in Leukemia research (01.04.2017)
Get full text
Journal Article
60 - Randomized Phase 2 Study of Guadecitabine in Patients with HMA-Naive Higher Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Savona, M.R., Garcia-Manero, G., Roboz, G.J., Walsh, K.J., Kropf, P.L., Issa, J.P., O’Connell, C.L., Tibes, R., Yee, K.W.L., Stock, W., Lunin, S., Berdeja, J.G., Naim, S., Hao, Y., Azab, M., Kantarjian, H.
Published in Leukemia research (01.04.2017)
Published in Leukemia research (01.04.2017)
Get full text
Journal Article
S879 RESULTS OF ASTRAL‐1 STUDY, A PHASE 3 RANDOMIZED TRIAL OF GUADECITABINE (G) VS TREATMENT CHOICE (TC) IN TREATMENT NAÏVE ACUTE MYELOID LEUKEMIA (TN‐AML) NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY (IC)
Fenaux, P., Gobbi, M., Kropf, P.L., Mayer, J., Roboz, G.J., Döhner, H., Krauter, J., Döhner, K., Robak, T., Kantarjian, H., Novak, J., Jedrzejczak, W., Thomas, X., Ojeda‐Uribe, M., Miyazaki, Y., Min, Y. H., Yeh, S.‐P., Brandwein, J., Gercheva‐Kyuchukova, L., Demeter, J., Griffiths, E., Yee, K., Azab, M., Issa, J.‐P.
Published in HemaSphere (01.06.2019)
Published in HemaSphere (01.06.2019)
Get full text
Journal Article